It seems kind of ridiculous to me. The Food and Drug Administration made King Pharmaceuticals
Is it really that hard to wait until 4:00 and not require trading to be halted? I understand that the agency is there to serve the public and not investors, but waiting an extra couple of hours really wouldn't make a bit of difference, considering doctors have been waiting years for abuse-resistant painkillers. And, call me paranoid, but yesterday's chart sure makes it look like someone knew about the approval before trading was stopped.
Even if the agency needs to show a little restraint, it's not like King is going to complain. An approval is an approval and this one helps justify its $1.6 billion purchase of Alpharma, which gave it Embeda.
Embeda is the first in a series of abuse-resistant pain drugs that companies are hoping to win approval for. King -- and especially its smaller partners, Pain Therapeutics
Embeda is a combination of extended-release morphine and naltrexone, which counteracts the morphine. When taken normally, the morphine releases slowly and the naltrexone passes through the patient. But if someone crushes or chews the drug to release the morphine all at once, the naltrexone should counteract the morphine and reduce the euphoric effects.
Now that it's approved, we get to see how much of the market Embeda can capture. It seems unlikely that a doctor would prescribe it to a young patient with questionable pain issues wearing a "legalize marijuana" t-shirt. But what about the average patient who the doctor doesn't have any reason to think is selling or abusing drugs? It may be difficult to justify the presumably higher price because generic versions of extended release morphine are available from Endo Pharmaceuticals
Regardless, the approval should boost sales that have been flagging since heart drug Altace went generic.
Will Embeda be king of the painkillers, or is prince or duke more its destiny? Let us know in the comments section below.
More from The Motley Fool
Is Pfizer the Right Stock to Retire With?
Stocks that give retirees what they want are incredibly valuable.
Here's How Endo Pharmaceuticals May Be Failing You
Keep your eye on margins.
5-Star Stocks Poised to Pop: Endo Pharmaceuticals
Market-trouncing returns could be written in these five stars.